Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 55Gastrointestinal 10CNS 9Tumor-Agnostic 3Breast 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1Head & Neck 1

Conditions

Precancerous Conditions 1Esophageal Neoplasms 1Barrett Esophagus 1

Interventions

Cyclophosphamide 5Decitabine 3Carboplatin 3Busulfan 3Radiotherapy 2Endoscopy 2Chemoradiotherapy 2Capecitabine 2sintilimab 1sargramostim 1liposomal doxorubicin 1fludarabine phosphate 1exemestane 1camrelizumab 1alethine 1Watchful Waiting 1Vincristine 1Ultrasonography, Doppler 1Rifampin 1Proton Therapy 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Papanicolaou Test 1Paclitaxel 1Observation 1Mycophenolic Acid 1Methylation 1Mass Spectrometry 1Liver Transplantation 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Erlotinib Hydrochloride × Other neoplasm × Clear all
NCT00566800 2013-09-17

Erlotinib in Treating Patients With Barrett Esophagus

National Cancer Institute (NCI)

Phase 1 Unknown
25 enrolled
GastrointestinalOther neoplasm

Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡